Classic symptoms of nOH include orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out.”1,2
Parkinson's disease (PD)
Multiple system atrophy (MSA)
Pure autonomic failure (PAF)
Non-diabetic autonomic neuropathy
Dopamine beta-hydroxylase deficiency
Vasodilators
Diuretics
Antihypertensives
Other medications
Hypovolemia
Cardiac insufficiency
Impaired venous return
*Based on short-term, placebo controlled clinical studies evaluating patient-reported nOH symptoms (e.g. dizziness/lightheadedness). Effectiveness beyond two weeks has not been established. See the USPI.
References:
1. NORTHERA [package insert]. Deerfield, IL: Lundbeck.
2. Freeman R. N Engl J Med. 2008;358(6):615-624.
3. Goldstein DS, Sharabi Y. Circulation. 2009;119(1):139-146.
4. Bradley JG, Davis KA. Am Fam Physician. 2003;68(12):2393-2398.
5. Gibbons CH, Schmidt P, Biaggioni I, et al. J Neurol. 2017;264(8):1567-1582.
1. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis. 2014;4(1):57-65. doi: 10.3233/JPD-130259. PMID: 24326693.
2. Isaacson S, Shill HA, Vernino S, et al. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303). J Parkinsons Dis. 2016 Oct 19;6(4):751-759. doi: 10.3233/JPD-160860. PMID: 27636856.
3. Goldstein DS, Sharabi Y. Circulation. 2009;119(1):139-146.
4. Bradley JG, Davis KA. Am Fam Physician. 2003;68(12):2393-2398.
5. Gibbons CH, Schmidt P, Biaggioni I, et al. J Neurol. 2017;264(8):1567-1582
6. Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015 Apr 15;30(5):646-54. doi: 10.1002/mds.26086. Epub 2014 Dec 9. PMID: 25487613.
7. Biaggioni I, Freeman R, Mathias CJ, et al. Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27. PMID: 25350981; PMCID: PMC4354798.
8. Biaggioni I, Freeman R, Mathias CJ, et al. Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015 Jan;65(1)302 supp.
If you have a question or would like access to medical and scientific information regarding NORTHERA or any Lundbeck product, go to www.Lundbeckmedinfo.com where you can submit a medical question to the Lundbeck Medical Information team.
Use
NORTHERA (droxidopa) is a prescription medication used to reduce dizziness, lightheadedness, or the “feeling that you are about to black out” in adults who experience a significant drop in blood pressure when changing positions or standing (called symptomatic neurogenic orthostatic hypotension (nOH)) and who have one of the following:
Effectiveness beyond 2 weeks of treatment has not been established, and your doctor will decide if you should continue taking NORTHERA.
IMPORTANT SAFETY INFORMATION
WARNING: SUPINE HYPERTENSION (this is high blood pressure while lying down)
When lying down, elevating the head and upper body lowers the risk of high blood pressure. Check your blood pressure in this position prior to starting and during NORTHERA treatment. If you experience high blood pressure, talk to your doctor about your NORTHERA treatment.
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088.
Use
NORTHERA (droxidopa) is a prescription medication used to reduce dizziness, lightheadedness, or the “feeling that you are about to black out” in adults who experience a significant drop in blood pressure when changing positions or standing (called symptomatic neurogenic orthostatic hypotension (nOH)) and who have one of the following:
Effectiveness beyond 2 weeks of treatment has not been established, and your doctor will decide if you should continue taking NORTHERA.
IMPORTANT SAFETY INFORMATION
WARNING: SUPINE HYPERTENSION (this is high blood pressure while lying down)
When lying down, elevating the head and upper body lowers the risk of high blood pressure. Check your blood pressure in this position prior to starting and during NORTHERA treatment. If you experience high blood pressure, talk to your doctor about your NORTHERA treatment.
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088.